Brown Tumour of Hyperparathyroidism

Definition

A brown tumour is a focal, tumour-like, lytic bone lesion that represents the localised end-stage of osteitis fibrosa cystica, the skeletal manifestation of hyperparathyroidism. Sustained excess parathyroid hormone (PTH) drives osteoclastic bone resorption; the resulting cavities fill with vascular fibrous tissue, osteoclast-type giant cells, reactive woven bone, microhaemorrhage and haemosiderin. The brown colour seen at operation comes from the haemosiderin and the rich vascularity, not from any pigment-producing cell.

The crucial point for the exam is that a brown tumour is a reactive process, not a true neoplasm. It has no metastatic potential, and it is histologically indistinguishable from giant cell tumour of bone, so the diagnosis depends on the biochemical context.

Why It Matters

• It is a classic giant cell tumour mimic - mislabelling it leads to the wrong operation.
• It can be the first presentation of otherwise occult hyperparathyroidism, including parathyroid carcinoma.
• It usually regresses after the parathyroid disease is treated, so the management priority is the gland, not the bone.

Key Epidemiology

Cause distribution:

• Secondary hyperparathyroidism (chronic kidney disease) is now the most common driver worldwide, reflecting the global dialysis population.
• Primary hyperparathyroidism (usually a single parathyroid adenoma) is the classic textbook cause; brown tumours are now an uncommon presentation because primary HPT is detected earlier on routine calcium testing.
• Tertiary hyperparathyroidism (autonomous glands after long-standing secondary HPT) is a less common but recognised cause.

Demographics and sites:

• Brown tumours are more frequent with more severe and longer-standing hyperparathyroidism.
• Common sites include the pelvis, ribs, mandible/maxilla (jaws), femur and other long bones.
• Lesions may be solitary or multiple; multiplicity should raise suspicion of an underlying metabolic cause.

The PTH-Osteoclast Axis

Parathyroid hormone is the master regulator of calcium. In excess it:

1. Increases osteoclastic bone resorption (indirectly, via the RANKL pathway on osteoblastic stromal cells), liberating calcium and phosphate from bone.
2. Increases renal calcium reabsorption and phosphate excretion.
3. Stimulates renal 1-alpha-hydroxylase, raising active vitamin D and gut calcium absorption.

When PTH is persistently high, resorption outpaces formation. Generalised demineralisation produces osteitis fibrosa cystica; focal exuberant resorption with reactive repair produces the discrete brown tumour.

Biochemical Patterns by Type

The biochemistry both explains the disease and tells you the type:

Alkaline phosphatase is typically raised, reflecting high bone turnover.

Histology

Characteristic findings:

• Numerous osteoclast-type multinucleated giant cells
• A vascular, fibrous (spindle-cell) stroma
• Haemosiderin deposition and areas of old and recent haemorrhage
• Reactive woven bone and a background of generalised osteoclastic resorption

The central teaching point: these features are indistinguishable from giant cell tumour of bone and overlap with giant cell reparative granuloma and the giant cell-rich variants of other lesions. The pathologist cannot reliably separate them on morphology alone - the diagnosis is confirmed by the biochemistry (raised PTH, abnormal calcium) and the clinical context.

Molecular Insight

Although classically considered purely reactive, molecular work shows that the giant cell-rich lesions of the jaws in hyperparathyroidism can harbour activating KRAS mutations with downstream MAPK/ERK pathway activation, placing them in the same RAS-driven spectrum as some histological mimics. This does not change the clinical message - treat the parathyroid disease - but it explains the close morphological overlap with other giant cell lesions.

Classifying the Lesion and Its Driver

How Patients Present

Skeletal symptoms:

• Bone pain, often diffuse
• A palpable or radiologically detected lytic lesion
• Pathological fracture through weakened bone (a common orthopaedic presentation)
• Skeletal deformity in severe, long-standing disease

Systemic features of hyperparathyroidism (bones, stones, groans, moans):

• Bones: bone pain, brown tumours, fractures
• Stones: renal calculi, nephrocalcinosis
• Abdominal groans: constipation, peptic ulcer, pancreatitis
• Psychic moans: fatigue, depression, poor concentration
• Proximal muscle weakness and hyperreflexia in severe disease

Important presenting scenarios:

• A jaw swelling referred from a dentist or maxillofacial team that turns out to be the first sign of hyperparathyroidism.
• A dialysis patient with bone pain and a lytic lesion (secondary HPT).
• An apparent giant cell tumour that does not fit - multiple lesions, abnormal calcium, or renal failure.

Examination

• Local tenderness or a firm swelling over the lesion
• Signs of the underlying disease (e.g. features of chronic kidney disease)
• Neurological assessment if a spinal lesion is suspected

Red Flags That Should Prompt a PTH Check

• A giant cell lesion in an unusual location for GCT (e.g. rib, jaw, multiple bones)
• Multiple lytic lesions
• A patient with renal failure or known hypercalcaemia
• Any giant cell lesion before a definitive operation is planned

Biochemistry - The Key to the Diagnosis

This is the single most important investigation. A giant cell lesion of bone must have calcium and PTH checked before treatment.

Imaging

Biopsy - Use With Caution

Biopsy shows giant cell-rich tissue but cannot distinguish brown tumour from giant cell tumour. If hyperparathyroidism has not been considered, a biopsy may even mislead towards an aggressive tumour diagnosis. The correct sequence is to check calcium and PTH first; biopsy is reserved for cases where the diagnosis remains uncertain after biochemistry, ideally in a specialist bone-tumour centre.

Principle: Treat the Gland First

The cornerstone of management is correcting the hyperparathyroidism. Once PTH normalises, the bone turnover falls and the great majority of brown tumours regress and remineralise, often without any direct bone surgery.

Treating the Hyperparathyroidism

Complications

From the lesion:

• Pathological fracture through weakened bone
• Neural compression from spinal or skull-base lesions
• Deformity and functional impairment in severe, long-standing disease

From the underlying hyperparathyroidism:

• Renal stones and nephrocalcinosis, progressive renal impairment
• Cardiovascular and soft-tissue calcification (especially in CKD)
• Severe hypercalcaemia and its systemic effects

From treatment:

• Hungry bone syndrome after parathyroidectomy
• Standard surgical risks if bone-directed surgery is undertaken
• Recurrence or persistence of brown tumours if the parathyroid disease is inadequately controlled

Prognosis

• The lesion itself is benign and reactive with no metastatic potential.
• With successful control of hyperparathyroidism, most brown tumours regress and remineralise, and the prognosis is excellent.
• Persistent or recurrent lesions usually reflect incompletely treated parathyroid disease rather than aggressive local behaviour.
• The overall outlook is determined largely by the underlying cause (e.g. the renal disease in secondary HPT, or the rare parathyroid carcinoma in primary HPT).

Why Examiners Love Brown Tumour

• It is the archetypal "do not be fooled" giant cell lesion - it tests whether you check biochemistry before operating.
• It links endocrinology, nephrology, radiology and orthopaedic oncology in one topic, ideal for a viva that crosses subspecialties.
• It rewards a candidate who states the principle clearly: treat the parathyroid disease first, operate on the bone only for mechanical or neurological reasons.

The One-Line Answer

If asked for the essence: "A brown tumour is a reactive giant cell lesion of hyperparathyroidism that is histologically identical to giant cell tumour of bone, so I would check the calcium and PTH, confirm and classify the hyperparathyroidism, and treat the parathyroid gland first - the lesion usually regresses, and I reserve bone surgery for fracture or neural compression."

Global Epidemiology

• Brown tumours are uncommon and becoming rarer in primary hyperparathyroidism in high-income settings, because routine calcium testing detects the disease before severe bone involvement develops.
• Secondary hyperparathyroidism from chronic kidney disease is now the leading driver globally, tracking the worldwide growth of the dialysis population.
• Common sites across populations include the pelvis, ribs, jaws and long bones; lesions may be solitary or multiple.

Side-by-Side Guidance and Consensus

Where guidance genuinely differs, the divergence is in the threshold for parathyroidectomy in secondary HPT (earlier surgery in some centres versus prolonged medical therapy with calcimimetics in others), not in the principle that the parathyroid disease drives the lesion.

Registry and Trial Evidence

• No implant joint-registry (NJR/AJRR/AOANJRR) tracks brown tumour, because management is metabolic and reconstruction (when needed) is fixation or grafting rather than arthroplasty.
• Evidence is built from case series and multicentre retrospective cohorts (e.g. CKD-MBD oral/maxillofacial series) and from the parathyroid disease trials underpinning calcimimetic and surgical practice.

High- vs Limited-Resource Practice